News and Announcements

Astrazeneca's Camizestrant cleared in the EU, Enhertu and Datroway pick up fresh recommendations

By Iain Gilbert

Date: Tuesday 26 May 2026

(Sharecast News) - Drugmaker Astrazeneca said on Tuesday that its breast cancer treatment camizestrant has secured EU approval, while its Enhertu and Datroway drug candidates also received fresh regulatory recommendations in Europe and the US.
The European Commission cleared camizestrant for use in combination with a CDK4/6 inhibitor as a first‑line...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page